➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LCL161

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug LCL161?

LCL161 is an investigational drug.

There have been 10 clinical trials for LCL161. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Neoplasms, Plasma Cell, and Lung Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Delta Clinical Research, LLC, and SCRI Development Innovations, LLC.

There are one hundred and sixty-six US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for LCL161
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaNovartis PharmaceuticalsPhase 1
A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNovartis PharmaceuticalsPhase 1
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesNovartis PharmaceuticalsPhase 1/Phase 2

See all LCL161 clinical trials

Clinical Trial Summary for LCL161

Top disease conditions for LCL161
Top clinical trial sponsors for LCL161

See all LCL161 clinical trials

US Patents for LCL161

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LCL161   Get Started Free Antibody drug conjugates Novartis AG (Basel, CH)   Get Started Free
LCL161   Get Started Free Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA)   Get Started Free
LCL161   Get Started Free Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.